Avandia Bigger Heart Risk Than Competitor: Study

Law360, New York (November 26, 2008, 12:00 AM EST) -- GlaxoSmithKline PLC's popular diabetes drug Avandia may pose a greater risk of death and heart failure than Takeda Pharmaceutical Co. Ltd.'s competing drug Actos, according to a recent study.

The study, published Nov. 24 in the Archives of Internal Medicine, looked at 28,361 patients older than 65 who were treated for diabetes from 2000 to 2005. Of those, 49.7 percent were treated with Avandia — generically known as rosiglitazone — and 50.3 percent were treated with Actos — generically called pioglitazone.

Both drugs have been linked...
To view the full article, register now.